Medical Genetics Unit, Department of Gynaecological, Obstetric, and Paediatric Sciences, University of Bologna, Bologna 40138, Italy.
Am J Hum Genet. 2011 Jan 7;88(1):115-20. doi: 10.1016/j.ajhg.2010.12.006.
THC2, an autosomal-dominant thrombocytopenia described so far in only two families, has been ascribed to mutations in MASTL or ACBD5. Here, we show that ANKRD26, another gene within the THC2 locus, and neither MASTL nor ACBD5, is mutated in eight unrelated families. ANKRD26 was also found to be mutated in the family previously reported to have an ACBD5 mutation. We identified six different ANKRD26 mutations, which were clustered in a highly conserved 19 bp sequence located in the 5' untranslated region. Mutations were not detected in 500 controls and are absent from the 1000 Genomes database. Available data from an animal model and Dr. Watson's genome give evidence against haploinsufficiency as the pathogenetic mechanism for ANKRD26-mediated thrombocytopenia. The luciferase reporter assay suggests that these 5' UTR mutations might enhance ANKRD26 expression. ANKRD26 is the ancestor of a family of primate-specific genes termed POTE, which have been recently identified as a family of proapoptotic proteins. Dysregulation of apoptosis might therefore be the pathogenetic mechanism, as demonstrated for another thrombocytopenia, THC4. Further investigation is needed to provide evidence supporting this hypothesis.
迄今为止,仅在两个家族中描述了常染色体显性血小板减少症 THC2,其归因于 MASTL 或 ACBD5 的突变。在这里,我们表明,ANKRD26(THC2 基因座内的另一个基因)而非 MASTL 或 ACBD5 在 8 个无关的家族中发生突变。ANKRD26 也在先前报道存在 ACBD5 突变的家族中发生突变。我们鉴定了六个不同的 ANKRD26 突变,这些突变聚集在高度保守的 19bp 序列中,该序列位于 5'非翻译区。在 500 个对照中未检测到突变,并且不在 1000 Genomes 数据库中。来自动物模型和 Watson 博士基因组的可用数据提供了证据,表明 ANKRD26 介导的血小板减少症的发病机制不是杂合不足。荧光素酶报告基因检测表明,这些 5'UTR 突变可能增强 ANKRD26 的表达。ANKRD26 是一个称为 POTE 的灵长类动物特异性基因家族的祖先,该家族最近被鉴定为一组促凋亡蛋白。因此,凋亡失调可能是发病机制,如另一种血小板减少症 THC4 所示。需要进一步的研究来提供支持该假设的证据。